MVD is considered the gold standard for treating trigeminal neuralgia when medication fails. Studies show long-term success rates of 80–90%, meaning most patients experience lasting pain relief or complete resolution. The effectiveness depends on factors like nerve compression severity and duration of symptoms.

At ABS, outcomes are enhanced through intraoperative nerve monitoring and high-definition imaging. Patients are typically discharged within a few days and resume normal activities in 2–3 weeks. For recurrent pain, radiosurgery or percutaneous procedures can also be considered.